February 2019 Issue Table Of Contents

From The Editor

• Trial By Media — Another Cost For Biopharma To Calculate?

Feature Articles

• A Look Inside J&J’s Partnering & Innovation-Building Model

Capitol Perspectives

• New Congress Wrestles With ACA And Budget Challenges: Rich Universities A Funding Source?

Patient Perspectives

• Preventing A Time Bomb: Patient Education

CEO Corner

• Considerations For Effective International Collaborations
• Lessons Learned: The Start Of mRNA Technology Development

From Principles and Policy to Execution

• Improving National Health Requires Reducing Prices And Increasing Access To Care

Companies To Watch

• Companies to Watch —Where Are They Now?

Industry Research

• mHealth In Clinical Trials: Why And How?

Inside The Industry

• How Will mHealth Benefit Clinical Trials?
• BeiGene Exec Talks Candidly About Quality, Compliance, And Outsourcing
• Foreign Investors Trigger ‘Critical Technology’ Review for Biotech
• Combatting Unproven Cell And Gene Therapies Through Regulation And Education
• Why Patent Protection Is Key To Commercializing Repurposed Drugs
• Digital Ledger Technologies Supporting Regulatory Exchange
• Maturity Assessment – The First Step Of The Pharma 4.0 Journey
• Why 2018 Was The Year Of Real-World Evidence For Biosimilars
• Master Trial Protocols: Better For Pharma, Better For Sites
• The Drug-Delivery Company That Partnerships Built
• Beyond The Printed Page Highlights

Industry Leader

• Pitching Investors: It’s About You, Not The Slide Deck

Leadership Lessons

• Confronting The Dilemmas Of Disruption

Ask The Board

• Should We Be Thinking About The Ethical Considerations Of Approving Clinical Trials Based On Scientific Merit/Patient Safety When 30 Percent Of Trials Will Never Complete Enrollment? Are We Breaking Our Commitment To Patients?
• When Do You Think Clinical Research Will Be A True Integral Option Within The Continual Care Of Patients, And What Do You See Will Help Drive It There?
• Virtual Clinical Trials Are Here. Do You Think The Pharma And Medical Industries Are Ready?